AstraZeneca's immune disorder drug succeeds in late-stage trial
Summary
AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into i...
AstraZeneca said on Thursday its experimental therapy gefurulimab met the main goal of a late-stage study looking into improving symptoms of a chronic, autoimmune condition known as generalised myasthenia gravis in adults.
Tags
AZN